Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Sep 13 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding a new agreement. The company has entered into an exclusive licensing and supply agreement for two MRI contrast agents in the US market. Zydus will market and distribute these products, while Viwit Pharmaceuticals will handle manufacturing and regulatory submissions. This marks the introduction of Gadolinium based MRI contrast agents into Zydus' injectable portfolio for the US.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 13, 2024, titled "Zydus announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable, contrast agents in the US.".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases